drugset / Trial / NCT06177431
An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease
Phase 1
Completed
12 enrolled
Neurizon Therapeutics Limited
Calvary Health Care Bethlehem · collabMacquarie University, Australia · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, 12-month open label extension study, following Phase 1 Study MON-2021-001, with a single dose of monepantel (MPL) once daily (QD) for the treatment of individuals with MND.
Timeline
- Start
- 2024-02-13
- Primary completion
- 2025-05-30
- Completion
- 2025-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Monepantel | Small molecule | 10 mg/kg | Oral |